

***Anti Annexin A5 antibodies in patients with
unexplained recurrent early pregnancy loss***

*Thesis
Submitted for Partial Fulfillment of
Master Degree in
Obstetrics and Gynecology*

By
Ehab Galal Ali Ghanema
M.B, B.Ch., 1999, Ain Shams University
Registrar of Obstetrics and Gynecology in
Om El-Masreyeen General Hospital
Giza-Egypt

Supervised by

Professor Ahmed Galal El-Leithy
Professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University

Dr. Sherif Fikry Hendawy
Assistant Professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University

*Faculty of Medicine
Ain Shams University
2006/2007*

Acknowledgement

First of all,

Thanks to GOD who allowed and helped me to accomplish this work.

I would like to express my deepest thanks and grateful appreciation to Prof. ***Dr. Ahmed Galal El-Leithy***, Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, whose great help, valuable advice and kind encouragement was a great help to me.

I also want to express my deepest thanks and gratefulness to ***Dr. Sherif Fikry Hindawy***, Assistant Professor of Obstetrics and Gynecology, Ain Shams University, for his help and close experienced supervision. His encouragement; guidance and valuable advice were behind the accomplishment of this work.

Special thanks to ***Dr. Sherien Hassan Atef***, Lecturer of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her careful supervision and help in constructing the work. I received a great help from her. No words can express, my thanks to her.

List of Abbreviations

aCL.....	anticardiolipin antibodies
AnxV.....	annexin V
APCR.....	activated protein C resistance
APS.....	antiphospholipid syndrome
aPS.....	antiphosphatidylserine
aPL	Antiphospholipid antibodies
β2GPI	B2 Glycoprotein 1
CV	Coefficients of variation
CVA	Cerebrovascular accident
D.M	Diabetes Mellitus
DVT	Deep vein thrombosis
ELISA.....	enzyme immunoassay
EPCR.....	Endothelial protein C receptor
G A	Gestational age
G S	Gestational sac
HCG.....	human chorionic gonadotropins
HELLP.....	syndrome hemolysis, elevated liver function test, Low platelet count
HUVEC.....	human umbilical vein endothelial cell cultures
IGFBP-1.....	insulin like growth factor binding protein
INR.....	international normalized ratio
IUGR.....	intrauterine growth retardation
IVF-ET.....	in vitro fertilization/embryo transfer
LA	lupus anticoagulant
LDA	Low-dose aspirin
MI	Myocardial infarction
No.	number
PAPI	placental anticoagulant protein I
PEA.....	phosphatidylethanolamine
PKC	protein kinase C
PS	phosphatidylserine
RSPL.....	Recurrent spontaneous pregnancy loss
RSA.....	recurrent spontaneous abortion
SLE.....	systemic lupus erythematosus
SSc.....	systemic sclerosis
STAT5.....	single transducer and activator of transcription 5
VACa.....	vascular anti-coagulant a

Abstract

The APS is an autoimmune disorder in which patients have antibodies to phospholipids or phospholipidbinding proteins (aPL) in combination with clinical manifestations such as vascular thrombosis and/or recurrent pregnancy losses. There are conflicting reports on the association of anti-annexin A5 antibodies with RSPL and reproductive failure in humans (*Levine et al, 2002*).

The objective of our study was to determine any association between the anti annexin V Ab IgG isotope and unexplained recurrent spontaneous abortion.

Methods: 50 women were included in the study. They were divided in to two groups: GROUP 1 patient group: included 25 cases that had a history of at least two or more successive unexplained recurrent abortion in their first trimester. GROUP 2 control group: included 25 cases that had at least two successful pregnancies and no history of pregnancy loss.

Results: We found that 10 cases of the 25 patients were positive for IgG ANX V Ab (40%), in contrast for 7 controls of 25 women found positive for IgG ANX V Ab (28%), and we found that 15 cases of 25 patients were positive (60%), in contrast for 8 controls of 15 women were found positive for IgM ANX Ab (53.3%).

Conclusion: Anti annexin A5 antibody of class IgG or IgM measured before the beginning of pregnancy are not predictive of the outcome of the next pregnancy.

Key words: APS, aPL, RSPL, ANX V Ab IgG, ANX Ab IgM.

Contents

- Introduction	8
- Aim of Work	13
- Review of Literature:	
- The antiphospholipid syndrome	14
- The antiphospholipid syndrome and recurrent miscarriage.....	31
- Annexin V	38
- Management of antiphospholipid syndrome during pregnancy.....	48
- Subjects and methods	54
- Results	71
- Discussion and conclusion	94
- Summary	104
- References	108
- Arabic summary	132

List of tables

No.	Title	page
1	Antigenic targets of antiphospholipid antibodies	36
2	Incubation scheme of annexin V Ab	67
3	Data of women included in the patients group	72
4	Data of women included in the control group	73
5	Comparison between patients and controls; general characteristics.	74
6	Comparison between patients and controls as regard age	75
7	Comparison between patients and controls as regard age groups	76
8	Number of abortions in patients group	77
9	The gestational age of last abortion among patients group	78
10	Number of patients according to result of ANX IgG & IgM test	79
11	Comparison between patients and controls as regard ANX IgG & IgM levels	80
12	Comparison between patients and controls IgG & IgM values	81
13	Correlation between both IgG & IgM and age, gestational age of last abortion and number of abortions according to Pearson correlation (r)	82

List of figures

No.	Title	
1	Phospholipids structure and phospholipids	15
2	Cell membrane drawing	16
3	Membrane lipids structure	16
4	Possible mechanisms of antiphospholipid antibody induced thrombosis	20
5	Immune recognition between APS and their antigen	37
6	Immunohistochemical localization of annexin A5	42
7	Model of anticoagulant role of annexin A5 and its disruption by APL Ab	44
8	Imaging by atomic force to the disruption of annexin A5 crystals	48
9	Mean age in both patients and control groups	83
10	Number of women in each age group in patients group	84
11	No. of women in each age group in controls group	85
12	Mean parity in both patients and controls groups.	86
13	Number of patients according to number of abortions	87
14	Percentage of patients according to G.A. of last abortion	88
15	Results of Anx. Ab IgG & IgM in both patients and controls groups	89
16	Percentage of patients according to positive or negative IgG level	90
17	Percentage of women according to positive or negative level of IgG in controls group	91
18	Percentage of patients according to positive or negative IgM level	92
19	Percentage of women according to positive or negative level of IgM in controls group	93

Introduction

Abortion is the most frequent complication of pregnancy, with an incidence ranging between 8% and 25%, depending on the population studied and the data collection method (*Regan & Rai, 2000*).

Pregnancy loss after implantation is frequent and idiopathic recurrent spontaneous abortion (RSA) is often seen in otherwise healthy women (*Mahjoub et al., 2005*).

Many factors are considered potentially liable to cause abortion: chromosomal abnormalities, uterine abnormalities, hormonal imbalances, coagulation defects, and infectious and immunological causes. In general, however, it is considered that chromosomal abnormalities are strongly prevalent before the 8th week of gestation and that a high percentage of the miscarriages occurring after the 8th week of gestation may have immunological causes (*Huang et al., 2005*).

The physiologic adaptation during pregnancy appears to be related to the development of an adequate placental circulation and provide a protective mechanism for homeostasis during delivery. The increase in procoagulant factors generates a hypercoagulable state and consequently increases thrombotic risk during pregnancy and the immediate postpartum period. The risk is higher in women with thrombophilic defect (*Bonnar et al., 1999*).

Thrombophilia is a multigenetic disorder caused by

inherited and acquired defects and can be defined as a predisposing to thrombosis. Antiphospholipid antibodies (aPL) are recognized as one of the most important causes of acquired thrombophilia (*Ana et al., 2002*).

Anti-phospholipids antibodies (aPL) are a heterogeneous group of autoantibodies. The persistent presence at medium-high levels of which is associated with the occurrence of thromboembolic events and fetal loss. (*Wilson et al., 1999*).

The anti-phospholipid syndrome is defined as the association of venous and/or arterial thrombosis, thrombocytopenia, and the production of autoantibodies against negatively charged phospholipids which are clinically associated with reproductive failure (repeated pregnancy loss, either early or late, intrauterine growth retardation, prematurity, placental abruption, induced hypertension in pregnancy, uteroplacental insufficiency, HELLP syndrome – haemolysis, elevated liver function test, Low platelet count) (*Rand et al., 2005*).

APL pregnancies are characterized by defective endovascular trophoblastic invasion of maternal uterine spiral arteries, extra villous trophoblast invasion being normal. Also aPL affect the expression of markers-prolactin and insulin like growth factor binding protein (IGFBP-1) of decidulisation, which is the process by which the endometrial stromal cells are transformed in the second half of menstrual cycle in readiness for implantation. aPL also has a direct inhibitory effect on the STAT5(single transducer and activator of transcription 5),intracellular signaling pathway which is involved in the expression of genes controlling decidualisation (*Rand et al,2003*).

Annexin A5, which was known as annexin V, a potent anticoagulant, was isolated and cloned from human umbilical cord arteries and placenta in the mid 1980s. It is composed of 319 amino acids. It is highly expressed by the apical surfaces of the syncytiotrophoblasts, which face the maternal circulation, and other cell types that serve as barrier function between tissues and body fluids (*Van Heerde et al., 2004*).

The potent anticoagulant properties of the protein result from that it is forming highly ordered 2-dimensional crystals that coat the external leaflets of phospholipids bilayers that shield them from availability for critical phospholipid-dependent coagulation reactions, which is an ideal anatomic position to promote blood fluidity in the uteroplacental circulation. Also it has been suggested that annexin V forms an antithrombotic shield around procoagulant anionic phospholipids, such as phosphatidylserine (PS) calcium dependent, which blocks their participation in phospholipid-dependent coagulation reactions, and that the binding of specific high-affinity antibodies to annexin V can compromise the antithrombotic shield and contribute to reproductive failure (*Rand et al., 2004*).

It has been demonstrated by atomic force microscopy that annexin V binding to phospholipids or its anticoagulant activity was significantly reduced by plasmas of patients with antiphospholipid antibodies and thrombosis compared with healthy controls and patients with thromboembolism and without antiphospholipid antibodies (*Rote et al., 2002*).

In addition, monoclonal antibodies against annexin V block intertrophoblastic fusion, suggesting another possible mechanism whereby these antibodies may induce miscarriage (*Rote et al., 2002*).

Anti-AnxV antibodies were present in 17% of subjects with recurrent miscarriage and were the only immunological marker among aCL, anti- β 2GPI, and antiprothrombin, which was correlated with the occurrence of miscarriage, though to a moderate extent (*Bizzaro et al., 2005*).

During embryonic and placental differentiation, a disruption of the lipid asymmetry occurs, leading to exposure of PS on the outer surface during the apoptotic processes accompanying the trophoblast differentiation. Blockage of PS by Abs hinders syncytium formation, thus enforcing apoptosis. Women with reproductive failure were found to have elevated levels of circulating aPS Abs associated with complications of Pregnancy (*Rote & Stetzer, 2003*).

An association between the presence of antiphosphatidylserine (aPS) and complication of pregnancy was documented in women with APS or pregnancy loss. This pathogenicity could be explained by more than one mechanism (*Manno et al., 2002*), for example:

- a) Shading the phosphatidylserine on the trophoblast cells interferes with signaling which leads to reduction in hCG production and invasion of the extracellular matrix to form the syncytiotrophoblast;
- b) Prevention of annexin-V binding to PS which was shown to restrict intrauterine growth (*Manno et al., 2002*).

These mechanisms indicate that the presence of these autoimmune factors involving production of antibodies targeting phospholipids (cardiolipin and phosphatidylserine) or phospholipid-binding proteins (b2GPI and annexin V) are closely related to RSA, via a mechanism which requires participation of immune and nonimmune factors in precipitating a prothrombotic state that favors pregnancy loss (*Walid Zammiti,et al., 2006*).

Aim of the work


The aim of the work is to estimate the level of Anti annexin A5 antibody, in the sera of unexplained recurrent pregnancy loss patients, and to find the relation between them.

THE ANTIPHOSPHOLIPID SYNDROME


PHOSPHOLIPIDS

Phospholipids are the primary components of cellular membranes. Each molecule contains a hydrophilic phosphate head and two hydrophobic fatty acid tails. This is important because phospholipids self assemble in water into a bilayer (*Wilson et al, 1999*).


The phospholipids head of the molecule determines the charge and function of molecule. Phospholipids can be anionic (negative charge, diphosphatidylglycerol [cardiolipin], phosphatidylserine, and phosphatidylglycerol), cationic (positive charge phosphatidylinositol and phosphatidic acid), or neutral charge (phosphatidylethanolamine and phosphatidylcholine). (*Mayes et al., 1993*).



Phospholipids structure (*Mayes et al., 1993*).




Diphosphatidyl-Glycerol




Phosphatidyl-Choline



Phosphatidyl-Ethanolamine



PhosphatidylInositol



Phosphatidyl-Serine

Figure (1): Phospholipids structure and phospholipids (*Mayes et al., 1993*).